8 - Diffuse Aggressive B-Cell Lymphomas

Abstract

This chapter covers the diffuse and aggressive B-cell lymphomas that arise in immunocompetent patients with a focus on the recent advances in our understanding of the clinical and biologic features that define these disease entities as reflected in the 2016 revision of the World Health Organization classification of lymphoid neoplasm. Diseases discussed include: diffuse large B-cell lymphoma (DLBCL), NOS; T-cell/histiocyte-rich large B-cell lymphoma; primary DLBCL of the central nervous system; primary cutaneous DLBCL, leg type; EBV-positive DLBCL, NOS; EBV-positive mucocutaneous ulcer; DLBCL associated with chronic inflammation; primary mediastinal large B-cell lymphoma; intravascular large B-cell lymphoma; ALK-positive large B-cell lymphoma; lymphomatoid granulomatosis; plasmablastic lymphoma; Burkitt lymphoma and Burkitt-like lymphoma with 11q aberration; high-grade B-cell lymphomas, NOS; and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 gene rearrangement (double and triple hit lymphomas).